NCT03241914View on ClinicalTrials.gov

Megestrol Acetate Plus LNG-IUS in Young Women With Early Endometrial Cancer

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

July 4, 2017

Primary Completion Date

June 18, 2020

Study Completion Date

June 18, 2020

Conditions
Endometrial Neoplasm Malignant Stage I
Interventions
DRUG

Megestrol Acetate

At a dosage of 160 mg/day

DEVICE

Levonorgestrel-releasing Intrauterine System(LNG-IUS)

levonorgestrel 52mg. It is a hormone-releasing T-shaped intrauterine system.

Trial Locations (1)

200011

Obstetrics and Gynecology Hospital, Fudan University, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT03241914 - Megestrol Acetate Plus LNG-IUS in Young Women With Early Endometrial Cancer | Biotech Hunter | Biotech Hunter